Effects of the CYP3A4 ô 1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: A meta-analysis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Shi, Wei Long ^a   Tang, Hui Lin ^a   Zhai, Suo Di ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; TACROLIMUS; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ARTICLE; CYP3A4 GENE; DATA ANALYSIS; EUROPEAN; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; META ANALYSIS (TOPIC); MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; POSTOPERATIVE PERIOD; TACROLIMUS TROUGH CONCENTRATION; WEIGHT ADJUSTED TACROLIMUS DAILY DOSE; WEIGHT ADJUSTED TACROLIMUS DAILY DOSE RATIO; ADULT; CAUCASIAN; GENETICS; KIDNEY TRANSPLANTATION; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; KIDNEY TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 84934922979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127995     Document Type: Article

References (34)

1. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, et al. (2006) Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 6: 1111-1131. PMID: 16613591
2. Kershner RP, Fitzsimmons WE (1996) Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62: 920-926. PMID: 8878385
3. Robles-Piedras AL, Gonzalez-Lopez EH (2009) Tacrolimus levels in adult patients with renal transplant. Proc West Pharmacol Soc 52: 33-34. PMID: 22128417
4. Kahan BD, Keown P, Levy GA, Johnston A (2002) Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clinical Therapeutics 24: 330-350. PMID: 11952020
5. Staatz CE, Tett SE (2004) Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics 43: 623-653. PMID: 15244495
6. Hronova K, Sima M, Svetlik S, Matouskova O, Slanar O (2014) Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol 7: 821-835. doi: 10.1586/17512433.2014.966811 PMID: 25301406
7. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, et al. (1994) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47: 727-735. PMID: 7510480
8. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, et al. (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23: 1315-1324. PMID: 8689938
9. Tuteja S, Alloway RR, Johnson JA, Gaber AO (2001) The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71: 1303-1307. PMID: 11397967
10. Tang HL, Xie HG, Yao Y, Hu YF (2011) Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 21: 713-720. doi: 10.1097/FPC.0b013e32834a48ca PMID: 21886016
11. Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, et al. (2014) Effect of CYP3A5∗3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J.
12. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA (2012) The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics 22: 642-645. doi: 10.1097/FPC.0b013e3283557c74 PMID: 22786571
13. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T (2014) The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 53: 123-139. doi: 10.1007/s40262-013-0120-3 PMID: 24249597
14. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5: 13. PMID: 15840177
15. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. (2009) STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6: e22. doi: 10.1371/journal.pmed.1000022 PMID: 19192942
16. Zhou X, Qian W, Li J, Zhang P, Yang Z, Wu L. (2013) Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis. Thrombosis research 132: 531-536. doi: 10.1016/j. thromres.2013.09.005 PMID: 24074702
17. Terrazzino S, Cargnin S, Del RM, Danesi R, Canonico PL, Genazzani AA. (2013) DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14: 1255-1272. doi: 10.2217/pgs.13.116 PMID: 23930673
18. Higgins JPT GSE (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration.
19. Kurzawski M, Dabrowska J, Dziewanowski K, Domanski L, Peruzynska M, Drozdzik M. (2014) CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 15: 179-188. doi: 10.2217/pgs.13.199 PMID: 24444408
20. Tavira B, Coto E, Diaz-Corte C, Alvarez V, Lopez-Larrea C, Ortega F. (2013) A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenetics and Genomics 23: 445-448. doi: 10.1097/FPC.0b013e3283636856 PMID: 23778326
21. Gervasini G, Garcia M, MacIas RM, Cubero JJ, Caravaca F, Benitez J. (2012) Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transplant International 25: 471-480. doi: 10.1111/j.1432-2277.2012.01446.x PMID: 22369694
22. Tavira B, Garcia EC, Diaz-Corte C, Ortega F, Arias M, Torres A, et al. (2011) Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clinical Chemistry and Laboratory Medicine 49: 825-833. doi: 10.1515/CCLM.2011.143 PMID: 21480817
23. Singh R, Srivastava A, Kapoor R, K. Sharma R, D. Mittal R (2009) Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn-Schmiedeberg's Archives of Pharmacology 380: 169-177. doi: 10.1007/s00210-009-0415-y PMID: 19343327
24. Kuypers DRJ, De Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clinical Pharmacology and Therapeutics 82: 711-725. PMID: 17495880
25. Hesselink DA, Van Schaik RHN, Van Der Heiden IP, Van Der Werf M, Smak Gregoor PJH, Lindemans J, et al. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics 74: 245-254. PMID: 12966368
26. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 Suppl 3: S1-S155. doi: 10.1111/j.1600-6143.2009.02834.x PMID: 19845597
27. Hashi S, Masuda S, Kikuchi M, Uesugi M, Yano I, Omura T, et al. (2014) Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity columnmediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. Transplant Proc 46: 758-760. doi: 10. 1016/j.transproceed.2013.11.060 PMID: 24767342
28. Ferraris JR, Argibay PF, Costa L, Jimenez G, Coccia PA, Ghezzi LF, et al. (2011) Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr Transplant 15:525-532. doi: 10.1111/ j.1399-3046.2011.01513.x PMID: 21711429
29. Chitnis SD, Ogasawara K, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. (2013) Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica 43: 641-649. doi: 10.3109/00498254. 2012.752118 PMID: 23278282
30. Liu YY, Li C, Cui Z, Fu X, Zhang S, Fan LL, et al. (2013) The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis. Gene 531: 476-488. doi: 10. 1016/j.gene.2013.09.024 PMID: 24042126
31. Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40: 159-168. PMID: 11327196
32. Benet LZ, Cummins CL, Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277: 3-9. PMID: 15158963
33. Wu CY, Benet LZ (2003) Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos 31: 1292-1295. PMID: 14570757
34. Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, et al. (2014) Effect of CYP3A5∗3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J 15: 38-48 doi: 10.1038/tpj.2014.38 PMID: 25201288